Literature DB >> 17196074

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

H A Tiddens1, D E Geller, P Challoner, R J Speirs, K C Kesser, S E Overbeek, D Humble, S B Shrewsbury, T A Standaert.   

Abstract

Several inhaled drugs for use by cystic fibrosis (CF) patients are formulated for nebulizer use only. This therapy is time consuming and includes the risk of contamination of the nebulizers. Dry powder inhalers (DPI) can be an attractive alternative for CF drugs. Inhaled flow rate and volume, and the device resistance are important determinants for optimal dispersion of drug from a DPI. It is important to understand how these variables interact in the CF population in order to properly design a new DPI formulation targeted for these patients. The objective of this study was to assess the inspiratory variables of a representative population of CF subjects 6 years and older with varying degrees of lung disease while inhaling through resistances that simulate DPI devices. Ninety-six stable CF patients were enrolled, ages 6-54 years, FEV(1) 19-126% predicted. Subjects inhaled forcefully through four different resistances (0.019, 0.024, 0.038, and 0.048 kP(0.5)/LPM, respectively), while inspiratory time (IT(DPI)), peak inspiratory flow (PIF(DPI)), and volumes (V(DPI)) were measured. For any resistance, inspired V(DPI) increased with the older age groups; PIF(DPI) was similar between adults and adolescents but lower in the children. Subjects with lower FEV(1) had lower V(DPI) and PIF(DPI). As resistance increased, PIF(DPI) decreased, IT(DPI) increased, with no significant change in V(DPI). At the lowest resistance mean PIF(DPI) was 105 LPM (range 45-163) for all patients; 112 LPM (range 75-163) in adults; and 89 LPM (45-126) in children. Mean inspired V(DPI) was 1.75 L for all patients; 2.2 L (0.8-3.7) in adults; and 1.2 L (0.5-1.8) in children. At the lowest resistance a minimal flow rate of 30, 45, and 60 LPM was attained in 100%, 99%, and 96% of all patients. Volumes of 1.0, 1.5, and 2.0 L were attained by 85%, 57%, and 30% of the patients. At the highest resistance mean PIF(DPI) was 52 LPM (range 26-70) for all patients; 55 LPM (40-70) in adults; and 47 LPM (26-62) in children. Mean inspired V(DPI) was 1.5 L in all patients; 1.9 L (0.9-3.5) in adults and 1.1 L (0.5-2.3) in children. At the highest resistance, a minimal flow rate of 30, 45, and 60 LPM was attained in 99%, 80%, and 22% of all patients. Volumes of 1, 1.5, and 2 L were attained in 84%, 45%, and 23% of the patients. We defined ranges for inspiratory variables in a diverse CF population for a range of device resistances that bracket those of current DPIs. The recorded inspiratory patterns can be used on the bench to design and test new dry powder formulations and devices to target the largest proportion of the CF population.

Entities:  

Mesh:

Year:  2006        PMID: 17196074     DOI: 10.1089/jam.2006.19.456

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  23 in total

1.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

Review 2.  Devices for dry powder drug delivery to the lung.

Authors:  Kai Berkenfeld; Alf Lamprecht; Jason T McConville
Journal:  AAPS PharmSciTech       Date:  2015-05-12       Impact factor: 3.246

Review 3.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

4.  Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.

Authors:  Dale Farkas; Michael Hindle; Serena Bonasera; Karl Bass; Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-08-29       Impact factor: 2.849

5.  Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.

Authors:  S Sommerfeld Ross; S Gharse; L Sanchez; J Fiegel
Journal:  Int J Pharm       Date:  2017-08-04       Impact factor: 5.875

6.  Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children.

Authors:  Conor A Ruzycki; Laleh Golshahi; Reinhard Vehring; Warren H Finlay
Journal:  Pharm Res       Date:  2014-01-07       Impact factor: 4.200

Review 7.  Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

8.  The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.

Authors:  Thaigarajan Parumasivam; Sharon S Y Leung; Patricia Tang; Citterio Mauro; Warwick Britton; Hak-Kim Chan
Journal:  AAPS J       Date:  2016-09-27       Impact factor: 4.009

9.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

Review 10.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.